The company said the funds will be used to expand its management team and complete commercialization of its mass spec multinozzle emitter array technology.
The platform can now measure RNA and proteins simultaneously at the single-cell level and can multiplex more than 100 proteins per experiment, the company said.
The company has developed a DNA barcode-based screening system that it said brings development time of its PCC affinity reagents down to around two weeks.
